Nambi V Aiyar

US Patent:

20020164707, Nov 7, 2002

Filed:

Jan 22, 2002

Appl. No.:

10/051186

Inventors:

John Adamou - St. David's PA, US
Nambi Aiyar - Berwyn PA, US
Derk Bergsman - Berwyn PA, US
Nabil Elshourbagy - West Chester PA, US
Li Yi - Sunnyvale CA, US
Norman Lee - Woodstock MD, US

Assignee:

Human Genome Sciences, Inc. - Rockville MD

International Classification:

C07K014/705
C12P021/02
C12N005/06
C07H021/04

US Classification:

435/069100, 435/320100, 435/325000, 530/350000, 536/023500

Abstract:

A human CGRP receptor polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for identifying antagonists and agonists to such polypeptide. Antagonists against such polypeptides may be used therapeutically to treat cancer, arthrits, pain, diabetes, migraine and inflammation and agonists which may be used to treat hypercalcemia, obesity, hypertension, and disorders of bone remodelling. Diagnostic assays are also disclosed which detect the presence of mutations in the nucleic acid sequences which encode the receptor polypeptide.

US Patent:

60748451, Jun 13, 2000

Filed:

Jan 28, 1999

Appl. No.:

9/238796

Inventors:

Nambi V. Aiyar - Berwyn PA
Jyoti Disa - King of Prussia PA

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

C12N 1512
C12N 510
C12N 1563
C07K 14705

US Classification:

435 691

Abstract:

BECRLR polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing BECRLR polypeptides and polynucleotides in screening assays to discover compounds that either agonize or antagonize the biological activity of the receptor. Such compounds are expected to be useful in treatment of human diseases, including, but not limited to: infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; stroke; ulcers; asthma; allergies; benign prostatic hypertrophy; migraine; vomiting; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, depression, delirium, dementia, and severe mental retardation; and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome.

US Patent:

61597007, Dec 12, 2000

Filed:

Jan 15, 1999

Appl. No.:

9/232857

Inventors:

Nambi V Aiyar - Berwyn PA
Robert S Ames - Havertown PA
Anne Romanic Arnold - Wynnewood PA
Kamal Al-Barazanji - Bishops Stortford, GB
Derk J Bergsma - Berwyn PA
Jon Chambers - Haslingfield, GB
Stephen A Douglas - Wayne PA
James J Foley - Radnor PA
Bernard Gout - Rennes, FR
Nassirah Khandoudi - Saint-Gregoire, FR
Henry M Sarau - Harleysville PA
Usman Shabon - Swarthmore PA
Robert N Willette - Pottstown PA

Assignee:

SmithKline Beecham Corporation - Philadelphia PA
SmithKline Beecham plc
SB Laboratoires Pharmaceutiques

International Classification:

G01N 33566
C12P 2100
C12N 506

US Classification:

435 72

Abstract:

Human GPR14 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Human GPR14 polypeptides and polynucleotides in the design of protocols for the treatment of ischemic coronary artery disease (angina and myocardial infarction); atherosclerosis; metabolic diseases (e. g. diabetes); CHF/myocardial dysfunction; arrhythmias; restenosis; hypertension; hypotension; pulmonary disease (hypertension, COPD, asthma); fibrotic vasculopathies (diabetes, SLE, AS, Reynaud's); cerebrovascular events (e. g. hemnorrhagic and ischemic stroke); neurogenic inflammation/migraine; hematopoictic disorders; ARDS; cancer; autoimmune diseases (e. g. HIV-1 and -2 infection and AIDS); gastrointestinal and genitourinary disturbances (e. g. ulcers) endocrine disorders; fibroproliferative disorders (e. g.